NurExone Biologic Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for NurExone Biologic.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	53.4%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	Low
Last updated	14 Nov 2024

Recent future growth updates

No updates

Recent updates

We're Keeping An Eye On NurExone Biologic's (CVE:NRX) Cash Burn Rate

Jun 12

Earnings and Revenue Growth Forecasts

TSXV:NRX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	N/A	N/A	N/A	1
12/31/2025	N/A	N/A	N/A	N/A	1
12/31/2024	N/A	N/A	N/A	N/A	1
6/30/2024	N/A	-4	-4	-4	N/A
3/31/2024	N/A	-4	-4	-4	N/A
12/31/2023	N/A	-4	-3	-3	N/A
9/30/2023	N/A	-4	-3	-3	N/A
6/30/2023	N/A	-4	-3	-3	N/A
3/31/2023	N/A	-7	-4	-4	N/A
12/31/2022	N/A	-8	-4	-4	N/A
9/30/2022	N/A	-8	-4	-4	N/A
6/30/2022	N/A	-7	-3	-3	N/A
3/31/2022	N/A	-4	-2	-2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if NRX's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if NRX's earnings are forecast to grow faster than the Canadian market

High Growth Earnings: Insufficient data to determine if NRX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if NRX's revenue is forecast to grow faster than the Canadian market.

High Growth Revenue: NRX is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if NRX's Return on Equity is forecast to be high in 3 years time

NurExone Biologic Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

New major risk - Shareholder dilution

NurExone Biologic Inc. announced that it expects to receive CAD 2 million in funding

New minor risk - Insider selling

NurExone Biologic Inc. Announces Significant Advancements in Their Manufacturing Process of Exosomes

NurExone Biologic Inc. Announces Further Expansion of ExoPTEN Patent Coverage

NurExone Biologic Inc. Announces Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s First Product ExoPTEN for Glaucoma

We're Keeping An Eye On NurExone Biologic's (CVE:NRX) Cash Burn Rate

New major risk - Financial position

New major risk - Shareholder dilution

NurExone Biologic Inc., Annual General Meeting, Jun 03, 2024

NurExone Biologic Inc. Expands Intellectual Property Portfolio

NurExone Biologic Inc. announced that it has received CAD 1.985758 million in funding

NurExone Biologic Inc. Appoints Eran Ovadya as Secretary

New major risk - Financial position

Nurexone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of Exopten Therapy for Acute Spinal Cord Injury Treatment

Nurexone Biologic Inc. Appoints Teodoro Forcht Dagi to Scientific Advisory Board and Advisory Committee

NurExone Biologic Inc. Secures Eureka Grant for Collaborative Partnership to Expand to Chronic Spinal Cord Injury Therapy

NurExone Biologic Inc. Moves Forward Towards Human Clinical Trials, Completes Pre-IND Meeting with FDA for Proprietary ExoPTEN Drug

Less than half of directors are independent

NurExone Biologic Inc. announced that it has received CAD 1.483501 million in funding

New minor risk - Shareholder dilution

NurExone Biologic Inc. Announces Board Changes

New minor risk - Shareholder dilution

NurExone Biologic Inc. announced that it expects to receive CAD 1.4 million in funding

NurExone Biologic Inc. Announces Advancements in Extracellular Vesicles Functionality with Enhanced Potency and Cellular Uptake for potentially better drug delivery

Nurexone Biologic Inc. Announces Board Changes

Nurexone Biologic Inc. Reports Positive Imaging Results from an Internal Preclinical Study of Its Investigational Drug ExoPTEN

NurExone Biologic Inc. Resignation of Eyal Flom from Board of Directors

Less than half of directors are independent

NurExone Announces Interim Positive Results of Internal Preclinical Study of Proprietary ExoPTEN Drug

United States Patent Office Allows Patent to NurExone Biologic Inc

Less than half of directors are independent

Nurexone Biologic Successfully Demonstrates Its Patent-Pending Platform Technology for Loading Exosomes with Therapeutic Molecules

Less than half of directors are independent

NurExone Biologic Inc. Announces Plan to Submit Pre- Investigational New Drug Meeting Request to U.S. Food and Drug Administration

NurExone Biologic Inc., Annual General Meeting, Dec 19, 2022

Less than half of directors are independent

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies